Research programme: prostate cancer therapy - Berg Pharma/CPDR/HJF
Latest Information Update: 21 Aug 2013
At a glance
- Originator Berg Pharma; Henry M. Jackson Foundation for the Advancement of Military Medicine; Uniformed Services University of the Health Sciences
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Prostate cancer
Most Recent Events
- 09 Aug 2013 Early research in Prostate cancer in USA (unspecified route)